Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Glioblastoma × sargramostim × Clear all

Phase

Phase 2 9 Phase 1 5 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Neuroblastoma 4 Leukemia 4 Leukemia, Myeloid, Acute 3 Sarcoma 2 Rhabdomyosarcoma 2 Melanoma 2 Malignant mesenchymal tumor 2 Lymphoma 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Breast Neoplasms 2 Uveal Melanoma 1 Urinary Bladder Neoplasms 1 Tongue Neoplasms 1 Stomatitis 1 Radiation Injuries 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Follicular 1 Leukemia, Promyelocytic, Acute 1 Leukemia, Myelomonocytic, Acute 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Monocytic, Acute 1 Leukemia, Megakaryoblastic, Acute 1 Leukemia, Erythroblastic, Acute 1

Interventions

Temozolomide 35 Radiotherapy 16 Lomustine 10 Bevacizumab 10 Carmustine 7 Radiation 6 Procarbazine 4 Surgical Procedures, Operative 3 Magnetic Resonance Spectroscopy 3 pembrolizumab 2 Tf-CRM107 2 Radiotherapy, Intensity-Modulated 2 Drug Therapy 2 Dihematoporphyrin Ether 2 DNA Methylation 2 Carboplatin 2 trans-sodium crocetinate 1 tofacitinib 1 sargramostim 1 rindopepimut 1 niraparib 1 marizomib 1 edotecarin 1 depatuxizumab mafodotin 1 contrast agent BR1 1 cediranib 1 carmustine, poliferprosan 20 drug combination 1 Vincristine 1 Valproic Acid 1 TVB-2640 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01480479 2018-01-16

ACT IV

Celldex Therapeutics

Phase 3 Completed

Brain Neoplasms, Glioblastoma, Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡